meta_pixel
Tapesearch Logo
Log in
The Energy Blueprint Podcast

The Hidden Link Between Lyme Disease and Alzheimer's (The MSIDS Protocol)

The Energy Blueprint Podcast

Ari Whitten

Alternative Health, Health & Fitness

4.6781 Ratings

🗓️ 30 May 2026

⏱️ 74 minutes

🧾️ Download transcript

Summary

What if some people diagnosed with chronic fatigue, fibromyalgia, autoimmune disease, anxiety, or even early Alzheimer's are actually dealing with an underlying infection that was never properly identified?

Today, I'm sharing my conversation with Dr. Richard Horowitz, a board-certified internist who has treated more than 13,000 patients with Lyme and tick-borne disease over the last four decades, many of whom had already seen countless doctors and collected diagnoses like chronic fatigue syndrome, fibromyalgia, depression, anxiety, multiple sclerosis, and early dementia before discovering Lyme may have been part of the picture.

Dr. Horowitz calls Lyme "the great imitator" because its symptoms can overlap with so many other conditions, and since 2016, Dr. Horowitz has published 11 papers on treatment approaches. In one of his latest studies, he and his colleagues explored a possible connection between Lyme disease and Alzheimer's biomarkers, reporting major improvements in certain inflammatory and cognitive-related markers after treatment.

We discuss his broader "MSIDS" model, which looks at chronic illness through a much wider lens. Instead of looking for one single cause, the model examines multiple overlapping factors that may contribute to illness, including infections, toxins, gut dysfunction, nutrient deficiencies, sleep issues, immune imbalance, and inflammation.

In this podcast, Dr. Horowitz and I discuss:

  • Why Lyme disease is called "the great imitator" and how it can resemble chronic fatigue syndrome, fibromyalgia, multiple sclerosis, anxiety, depression, and Alzheimer's disease

  • The often-overlooked migratory pain that is one of the hallmark symptoms of chronic Lyme

  • The Lyme symptom questionnaire, which he developed and validated on 6,400 patients

  • How research from Johns Hopkins and other universities changed our understanding of Lyme as a persistent infection

  • Why Dr. Horowitz began using drugs like dapsone and rifampin in Lyme treatment protocols

  • His published research on dapsone combination therapy and the improvements he has observed in patients

  • His recent findings on Lyme disease and Alzheimer's biomarkers, including reductions in tau217 levels

  • Dr. Horowitz's unique MSIDS model and the many overlapping factors that may drive chronic illness

  • Why chronic illness rates continue rising and what conventional medicine may still be missing

  • Why Dr. Horowitz believes recovery is possible, even for patients who have been sick for years

 

Transcript

Click on a timestamp to play from that location

0:00.0

The anti-ameloid monoclonal antibodies like lachanamab dinanamab that are out there,

0:05.4

they lower petal by about 23% over six years.

0:09.3

We lowered it by 63% in nine weeks.

0:12.5

The reason being, the amyloid that was being produced in the brain,

0:16.6

so the phosphorylated tau, was coming from an infection.

0:19.2

Hey, this is Ari.

0:20.0

Welcome back to the Energy Blueprint podcast.

0:22.4

With me in this episode is Dr. Richard Horowitz,

0:25.2

who is a board-certified internist and medical director

0:28.7

of the Hudson Valley Healing Arts Center,

0:31.2

an integrative medical center,

0:32.6

which combines both mainstream and integrative approaches

0:35.9

in the treatment of Lyme disease and other tick-borne

0:38.5

disorders. He's treated over 13,000 Lyme and tick-borne disease patients over the last four decades,

0:46.5

with patients coming from all over the world to his clinic, and he's advised the HHS, the New York

0:52.8

State Department of Health, as well as governmental agencies all over the world.

0:57.7

His third book titled Ending Chronic Illness is coming out in October of this year, 26.

1:05.0

And the broader discussion of this is, as you'll hear in this podcast, he's developed this framework

1:11.8

over the last four decades of treating thousands of patients. He's developed this 16-point,

1:17.9

what he calls MSIDS, MS-I-D-S-I-D-S framework for understanding and treating chronic disease.

1:26.6

And this was originally developed in the context of Lyme disease, chronic disease. And this was originally developed in the context

1:29.9

of Lyme disease, chronic Lyme disease,

...

Transcript will be available on the free plan in 23 days. Upgrade to see the full transcript now.

Disclaimer: The podcast and artwork embedded on this page are from Ari Whitten, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of Ari Whitten and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.

Copyright © Tapesearch 2026.